Pembrolizumab: observed

171 studies: patients on it are followed, or it is given outside a trial. Page 2 of 2. Open to participants first (66), then studies with results posted, then the rest; newest registration first within each.

• Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal CancerCompletedNCT05942768Report a problem
• EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance DatabaseCompletedNCT05934214Report a problem
• Emulation of the KEYNOTE-189 Trial Using Electronic Health RecordsCompletedNCT05908799Report a problem
• Pharmacokinetic Profiling of Pembrolizumab and Nivolumab in Patients With Melanoma and/or Non-Small Cell Lung CancerCompletedNCT05740501Report a problem
• Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of MelanomaCompletedNCT05714371Report a problem
• Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor BurdenCompletedNCT05611229Report a problem
• Efficacy and Safety of Neoadjuvant Pembrolizumab in III-IVA Resectable Oral Squamous Cell CarcinomaStatus unknownNCT05578170Report a problem
• Neo-Sequence 1: Neoadjuvant Chemotherapy With or Without Antiangiogenesis and Sequential Immunotherapy for HER2-negative MMR-proficient Locally Advanced Gastric or Gastroesophageal AdenocarcinomaCompletedNCT05540145Report a problem
• A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic TherapyCompletedNCT05432622Report a problem
• Intermediate-size IND for Treatment of KRAS G12V-mutant TumorsNo longer availableNCT05389514Report a problem
• A Study of Lenvatinib in Combination With Pembrolizumab in Korean PatientsCompletedNCT05375136Report a problem
• TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCCCompletedNCT05332821Report a problem
• TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCCCompletedNCT05332496Report a problem
• Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH)CompletedNCT05321212Report a problem
• Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative DeliriumCompletedNCT05273827Report a problem
• MicroOrganoSphere (MOS) Drug Screen Pilot Trial in Colorectal CancerCompletedNCT05189171Report a problem
• Pembrolizumab and Anlotinib in the Treatment of High-Grade Serous Ovarian CancerCompletedNCT05188781Report a problem
• Efficacy and Safety of Immunotherapy in Non-small Cell Lung Cancer With Uncommon Histological TypeCompletedNCT05023837Report a problem
• Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung CancerActive, not recruitingNCT04994795Report a problem
• Efficacy and Safety of TACE in Combination With ICIs for HCC: a Real-world StudyCompletedNCT04975932Report a problem
• The Prospective Non-randomized Case-control Study From Real-world Lung Cancer PatientsCompletedNCT04909164Report a problem
• Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint InhibitorsCompletedNCT04898751Report a problem
• Energy for LymphocytesCompletedNCT04879316Report a problem
• Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid TumorsStatus unknownNCT04860076Report a problem
• Circulating Tumor DNA Alterations in Non-small Cell Lung Cancer Patients Treated With PembrolizumabTerminatedNCT04791215Report a problem
• Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal CancerStatus unknownNCT04771715Report a problem
• Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in ChinaStatus unknownNCT04740996Report a problem
• Efficacy and Safety of Eribulin in the Treatment of Advanced Breast CancerStatus unknownNCT04683445Report a problem
• Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCCStatus unknownNCT04639284Report a problem
• Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular CarcinomaCompletedNCT04627012Report a problem
• Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN)CompletedNCT04606940Report a problem
• Liver Toxicity in Lung Cancer Patients Treated With Immune-checkpoint Inhibitors.Status unknownNCT04595734Report a problem
• Drug Concentration Monitoring of Pembrolizumab in Non-Small Cell Lung Cancer PatientsTerminatedNCT04557007Report a problem
• Axitinib Therapy Management StudyWithdrawnNCT04555603Report a problem
• Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/MelanomaCompletedNCT04490564Report a problem
• BLood Groups as Biomarker to Optimize Odds of Response to Anti-PD-1 DrugsTerminatedNCT04473027Report a problem
• QUantitative Assessment of Swallowing After Radiation (QUASAR)Status unknownNCT04359199Report a problem
• Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 InhibitorsStatus unknownNCT04355806Report a problem
• A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With ChemotherapyStatus unknownNCT04306042Report a problem
• Immune Related-adverse Events in Patients Receiving Immune Checkpoint InhibitorsStatus unknownNCT04268368Report a problem
• A Single Patient Will be Treated With Individual Patient TCR-Transduced PBLNo longer availableNCT04194190Report a problem
• Real World Observational Study of Pembrolizumab for Chinese Advanced NSCLCStatus unknownNCT04153097Report a problem
• Breathomics as Predictive Biomarker for Checkpoint Inhibitor ResponseCompletedNCT04146064Report a problem
• Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of PembrolizumabNo longer availableNCT04135092Report a problem
• PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort StudyStatus unknownNCT04115410Report a problem
• Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC PatientsCompletedNCT04076228Report a problem
• Gut Microbiome in Colorectal CancerCompletedNCT04054908Report a problem
• Real World Study of Four PD-1 Agents in ChinaStatus unknownNCT03966456Report a problem
• Autoantibodies in Treatment with Immune Checkpoint Inhibitors (AUTENTIC)CompletedNCT03868046Report a problem
• A Study To See Why Patients Agree To or Decline To Have Treatment After SurgeryCompletedNCT03843593Report a problem
• A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint InhibitorsActive, not recruitingNCT03695952Report a problem
• A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen.CompletedNCT03695835Report a problem
• Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReActionCompletedNCT03492242Report a problem
• Improved Therapy Response Assessment in Metastatic Brain TumorsActive, not recruitingNCT03458455Report a problem
• Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint InhibitionCompletedNCT03453892Report a problem
• Biomarkers of Immune-Related ToxicityActive, not recruitingNCT03409016Report a problem
• Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse ReactionsCompletedNCT03387540Report a problem
• A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC PatientsStatus unknownNCT03373955Report a problem
• Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic MelanomaCompletedNCT03356470Report a problem
• Study of Adverse Renal Effects of Immune Checkpoints InhibitorsCompletedNCT03316417Report a problem
• Expanded Access for Pembrolizumab (MK-3475)No longer availableNCT03311542Report a problem
• Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma PatientsCompletedNCT03197636Report a problem
• Immune Checkpoint Inhibitors and Pre-existing Autoimmune DiseasesCompletedNCT03140137Report a problem
• Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)CompletedNCT03061955Report a problem
• Immunophenotyping of Melanoma Patients on Treatment With PembrolizumabCompletedNCT02909348Report a problem
• Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma PatientsTerminatedNCT02744209Report a problem
• Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With PembrolizumabCompletedNCT02600169Report a problem
• Identification of Predictive Parameters for Colitis in Melanoma Patients Treated With Immunotherapy.CompletedNCT02600143Report a problem
• Multi-Centre, Retrospective, Open Label Study, to Validate ML-PrediCare by Patients With Melanoma Under 1st and 2nd Lines of ImmunotherapyStatus unknownNCT02581228Report a problem
• Investigation of Circulating Tumor Cells From Cancer Patients Undergoing Radiation TherapyCompletedNCT02449837Report a problem
• Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)No longer availableNCT02083484Report a problem

← Pembrolizumab